Times Square Capital Management, LLC Chemo Centryx, Inc. Transaction History

Times Square Capital Management, LLC

$6.49 Billion
Q3 2024

Shares

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q2 2022 Aug 05, 2022	BUY	$15.36 - $27.51 $202,752 - $363,132	13,200 Added 46.32%	41,700 $1.03 Million
Q1 2022 May 06, 2022	BUY	$22.22 - $39.12 $99,990 - $176,040	4,500 Added 18.75%	28,500 $714,000
Q4 2021 Feb 04, 2022	BUY	$18.38 - $40.5 $441,120 - $972,000	24,000 New	24,000 $874,000
Q2 2021 Aug 09, 2021	SELL	$9.59 - $50.88 $14.8 Million - $78.7 Million	-1,547,710 Closed	0 $0
Q1 2021 May 12, 2021	BUY	$49.53 - $68.4 $50.3 Million - $69.4 Million	1,014,625 Added 190.33%	1,547,710 $79.3 Million
Q4 2020 Feb 12, 2021	BUY	$47.25 - $65.16 $25.2 Million - $34.7 Million	533,085 New	533,085 $33 Million

Others Institutions Holding CCXI

# of Institutions

6

Shares Held

66.3K

Call Options Held

0

Put Options Held

0

About ChemoCentryx, Inc.

Ticker CCXI
Exchange NASDAQ
Shares Outstandng 71,919,696
Market Cap $3.68M
Description
ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil...

More about CCXI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Times Square Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Times Square Capital Management, LLC with notifications on news.